Novonensis expects 2024 adjusted EBITDA margin of 35%

Novozymes A/S

21/03/2024 06:38

COPENHAGEN, March 21 (Reuters) - Denmark's Novonensis
 NSISb.CO , created from the merger of food ingredients and
enzymes makers Novozymes and Chr. Hansen, on Thursday predicted
a 2024 adjusted margin on its earnings before interest, tax,
depreciation and amortization of around 35%.

 (Reporting by Louise Breusch Rasmussen, editing by Terje
Solsvik)
 ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))